Suchergebnisse - "Ghosh, Alakendu"

PubPharm (9)

1

Methotrexate and theaflavin-3, 3'-digallate synergistically restore the balance between apoptosis and autophagy in synovial fibroblast of RA : an ex vivo approach with cultured human RA FLS

enthalten in: Inflammopharmacology | 2021

von Misra, S. | Bagchi, A. | Sarkar, A. | +11

2

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients Receiving Combination Therapy : Comment on the Article by Curtis et al

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2021

von Roongta, R. | Mondal, S. | Ghosh, A.

CommentOn: Arthritis Rheumatol. 2021 May;73(5):759-768. - PMID 33205906

3

Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis : An observational study

enthalten in: Indian journal of pharmacology | 2016

von Dubey, L. | Chatterjee, S. | Ghosh, A.

4

Itolizumab in combination with methotrexate modulates active rheumatoid arthritis : safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study

enthalten in: Clinical rheumatology | 2016

von Chopra, A. | Chandrashekara, S. | Iyer, R. | +10

5

Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study

enthalten in: Indian journal of pharmacology | 2016

von Dubey, L. | Chatterjee, S. | Ghosh, A.

6

Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study

enthalten in: Clinical rheumatology | 2015

von Chopra, A. | Chandrashekara, S. | Iyer, R. | +10

7

Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study

enthalten in: Clinical rheumatology | 2015

von Chopra, A. | Chandrashekara, S. | Iyer, R. | +10

8

Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study

enthalten in: Clinical rheumatology | 2015

von Chopra, A. | Chandrashekara, S. | Iyer, R. | +10

9

Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis--a single centre study using non-biologic drugs

enthalten in: The Journal of the Association of Physicians of India | 2013

von Chatterjee, S. | Sarkate, P. | Ghosh, S. | +2

CommentIn: J Assoc Physicians India. 2013 Aug;61(8):529. - PMID 24818334

1
[1]